Hogan Lovells advises Istituto Gentili on the exclusive partnership with CStone Pharmaceuticals

Press releases | 25 July 2025

Global law firm Hogan Lovells has advised Istituto Gentili, a biopharmaceutical company rapidly expanding in the field of oncology at European Level, on an exclusive partnership with CStone Pharmaceuticals, an innovation-driven biopharmaceutical company focused on oncology. The partnership aims to exclusively commercialize sugemalimab, an anti-PD-L1 monoclonal antibody approved in the EU and UK for the treatment of stage IV non-small cell lung cancer (NSCLC), in 23 European countries and the UK.

The Hogan Lovells team that advised on the transaction was led by partner Andrea Pretti and included partner Alessandro Seganfreddo and associate Stefania Maracich. Head of Tax Serena Pietrosanti together with counsel Maria Cristina Conte and associate Mariateresa Soave Carparelli advised on the fiscal aspects of the transaction